Take the U.S. company Moderna. It is likely to present the first interim results on the efficacy of its own coronavirus vaccine in the next few days, which is also based on mRNA technology.
Like BioNTech, Moderna also aspires to become a platform company. And it has been showered with money from U.S. investors since its founding. Indeed, prior to the pandemic, the company managed to attract 10 times more capital than its competitor BioNTech in Germany
Fuente del contexto
Der Spiegel (english version)
Tipo de fuente
Revista
Autor
Tim Bartz, Markus Brauck, Martin U. Müller und Thomas Schulz